title: Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers.
abstract: OBJECTIVE
  This study assessed the effect of mirabegron on ocular safety in healthy volunteers.
  
  
  METHODS
  This was an 8-week, randomized, double-masked, placebo-controlled study.
  
  
  METHODS
  Consenting adults aged ≥18 years with a normal intraocular pressure (IOP, ≥10 to ≤21 mmHg) were eligible to enter the study. Of the 321 randomized subjects, 305 completed the study. Subjects were randomized 1:1 to a supratherapeutic dose of oral mirabegron 100 mg or placebo once daily for 56 days. The IOP was measured at screening, baseline, day 10, and day 56/end of treatment using Goldmann applanation tonometry. Visual acuity and biomicroscopy were also evaluated. The primary endpoint was the mean change from baseline in the IOP at 56 days or end of treatment with mirabegron versus placebo. Secondary outcome variables included change from baseline to day 10 in the IOP, and increases in the IOP of ≥6 mmHg and ≥10 mmHg in either eye from baseline to day 10 and day 56.
  
  
  RESULTS
  The mean (standard error, SE) IOP at baseline was 15.3 (0.16) mmHg for mirabegron and 15.4 (0.16) mmHg for placebo; values at day 56 were 15.0 (0.16) mmHg and 15.2 (0.17) mmHg, respectively. The adjusted mean IOP change from baseline to day 56 was -0.3 mmHg for mirabegron and -0.2 mmHg for placebo (-0.1 mmHg difference [95% confidence interval, CI, -0.4 to 0.3]). For the primary endpoint, mirabegron was noninferior to placebo, based on the prespecified limit of 1.5 mmHg. No statistically significant treatment effects on the IOP were seen at day 10. No subject discontinued due to increased IOP. Clinically significant increases from baseline in the IOP occurred rarely and only with placebo treatment. Changes in the visual acuity and biomicroscopy were not suggestive of a mirabegron effect. No treatment-emergent adverse event (AE) of glaucoma was reported.
  
  
  CONCLUSIONS
  Mirabegron 100 mg orally once daily for 8 weeks of treatment does not increase the IOP, and was generally safe and well tolerated.
authors.affiliation: PharmaLogic Development, Inc., San Rafael, CA 94903, USA. gary_novack@pharmalogic.com
authors.forename: Gary D
authors.initials: GD
authors.lastname: Novack
authors.forename: Richard A
authors.initials: RA
authors.lastname: Lewis
authors.forename: Roger
authors.initials: R
authors.lastname: Vogel
authors.forename: Neha
authors.initials: N
authors.lastname: Sheth
authors.forename: Dennis
authors.initials: D
authors.lastname: Swearingen
authors.forename: Scott
authors.initials: S
authors.lastname: Rasmussen
authors.forename: Gary
authors.initials: G
authors.lastname: Hantsbarger
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Martin
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005123:Eye / Q000187:drug effects*; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D013844:Thiazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000083:Acetanilides; D013844:Thiazoles; C520025:mirabegron